Tarsus Pharmaceuticals, Inc. (TARS)
Free
No email, no account, no signup.
Pulling latest news for Tarsus Pharmaceuticals, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Ophthalmic biopharmaceuticals
Market Cap
$2.8B
We're already tracking Tarsus Pharmaceuticals, Inc. — here are the latest events we've registered
Recent News
- On May 6, 2026, Tarsus reported Q1 2026 net sales of $145.4 million for XDEMVY, representing over 85% year-over-year growth. The company also initiated a Phase 2 clinical trial for TP-05, an investigational oral treatment for Lyme disease prevention. Additionally, the company's lead product received regulatory approval in China in March 2026.
Want to know how this news affects Tarsus Pharmaceuticals, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Tarsus Pharmaceuticals, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.